tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Supernus Pharmaceuticals Inc

SUPN
Add to Watchlist
27.620USD
+1.460+5.58%
Close 11-09 16:00（ET）
1.61BMarket Cap
LossP/E TTM

Supernus Pharmaceuticals Inc

27.620
+1.460+5.58%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

SUPN Financials

See Supernus Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.
Key Financial Ratios
Market Cap
1.61B
Dividend TTM
0.00
P/E TTM
-54.11
EPS TTM
-0.51
Revenue
1.24B
Net Profit
73.86M
ROE
-2.75%
ROA
-2.04%
Supernus Pharmaceuticals Inc Earnings Date
Latest Release
Oct 29, 2026
EPS / Forecast
1.16/0.49
Revenue / Forecast
356.00M/215.92M

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q3
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
Financial Indicators
EPS
245.53%1.16
-350.30%-1.01
81.21%-0.04
-125.88%-0.07
-214.29%-0.80
10.86%0.40
-9467.70%-0.21
1185.30%0.28
338.61%0.70
2475.41%0.36
-99.27%0.00
-95.43%0.02
---0.29
---0.02
--0.31
--0.47
--0.66
----
----
----
Revenue
85.32%356.00M
32.40%219.06M
38.63%207.71M
21.48%211.57M
9.34%192.10M
-1.71%165.45M
4.30%149.82M
5.99%174.16M
14.17%175.69M
24.17%168.32M
-6.58%143.64M
-1.80%164.31M
-13.24%153.88M
-20.28%135.56M
0.82%153.76M
5.20%167.33M
19.46%177.35M
20.32%170.05M
16.48%152.51M
10.79%159.05M
Net Profit
403.65%137.00M
-359.44%-58.37M
80.61%-2.29M
-126.78%-4.11M
-217.20%-45.12M
12.97%22.50M
-9637.90%-11.83M
1204.51%15.33M
340.97%38.50M
2496.63%19.92M
-99.27%124.00K
-95.39%1.18M
-1013.44%-15.98M
-110.57%-831.00K
-33.84%16.95M
943.45%25.48M
-91.89%1.75M
-66.85%7.87M
349.88%25.62M
-92.06%2.44M
Net Margin
263.86%38.48%
-295.95%-26.65%
86.01%-1.10%
-122.05%-1.94%
-207.18%-23.49%
14.93%13.60%
-9244.96%-7.89%
1130.78%8.80%
311.06%21.91%
2030.16%11.83%
-99.22%0.09%
-95.30%0.72%
---10.38%
---0.61%
--11.02%
--15.23%
--7.05%
----
----
----
Gross Margin
13.14%87.64%
-5.41%73.07%
0.16%76.39%
-1.53%78.43%
-1.82%77.47%
-0.21%77.25%
2.20%76.27%
5.87%79.65%
7.41%78.90%
11.21%77.41%
4.00%74.63%
1.79%75.23%
--73.46%
--69.61%
--71.76%
--73.91%
--74.76%
----
----
----
Debt to assets ratio
--36.64%
----
----
----
----
----
----
----
----
----
----
-100.00%0.00%
--0.00%
--0.00%
--26.84%
--23.61%
--23.71%
----
----
----
Income Statement
Revenue
85.32%356.00M
32.40%219.06M
38.63%207.71M
21.48%211.57M
9.34%192.10M
-1.71%165.45M
4.30%149.82M
5.99%174.16M
14.17%175.69M
24.17%168.32M
-6.58%143.64M
-1.80%164.31M
-13.24%153.88M
-20.28%135.56M
0.82%153.76M
5.20%167.33M
19.46%177.35M
20.32%170.05M
16.48%152.51M
10.79%159.05M
Operating profit
1948.52%190.00M
-125.07%-3.04M
-128.85%-5.94M
-42.03%17.77M
-76.71%9.28M
-33.34%12.14M
38.89%-2.60M
73.46%30.66M
389.42%39.83M
203.57%18.21M
-220.37%-4.25M
-48.52%17.68M
634.34%8.14M
-255.01%-17.59M
34.08%3.53M
16.32%34.33M
-104.66%-1.52M
-55.27%11.35M
-81.51%2.63M
-34.40%29.52M
Net Profit
403.65%137.00M
-359.44%-58.37M
80.61%-2.29M
-126.78%-4.11M
-217.20%-45.12M
12.97%22.50M
-9637.90%-11.83M
1204.51%15.33M
340.97%38.50M
2496.63%19.92M
-99.27%124.00K
-95.39%1.18M
-1013.44%-15.98M
-110.57%-831.00K
-33.84%16.95M
943.45%25.48M
-91.89%1.75M
-66.85%7.87M
349.88%25.62M
-92.06%2.44M
Balance Sheet
Current assets
34.70%800.00M
-2.08%723.50M
6.40%731.58M
-6.11%644.18M
-7.20%593.89M
25.02%738.87M
26.32%687.58M
39.13%686.07M
42.43%640.00M
39.54%591.00M
-38.38%544.32M
-32.83%493.11M
-32.31%449.36M
-32.25%423.54M
55.38%883.34M
22.04%734.15M
-0.67%663.89M
-2.21%625.12M
-2.99%568.52M
-4.57%601.59M
Total current liabilities
293.49%1.30B
21.31%347.38M
32.71%373.93M
15.65%338.17M
13.42%330.63M
-7.22%286.36M
-10.42%281.77M
0.76%292.40M
1.38%291.51M
22.20%308.66M
-57.00%314.55M
-57.82%290.20M
-60.39%287.53M
-65.66%252.59M
157.08%731.54M
118.14%687.96M
209.31%725.99M
159.50%735.54M
18.17%284.56M
28.67%315.38M
Total assets
-6.18%1.33B
3.31%1.43B
11.39%1.50B
6.18%1.45B
5.74%1.42B
5.06%1.38B
3.31%1.35B
7.08%1.37B
4.48%1.34B
1.76%1.32B
-27.22%1.30B
-24.95%1.28B
-24.10%1.29B
-23.71%1.29B
9.29%1.79B
0.79%1.70B
8.88%1.69B
7.75%1.69B
8.76%1.64B
12.30%1.69B
Total liabilities
276.13%1.39B
24.61%396.88M
33.90%423.92M
17.63%390.93M
10.29%370.09M
-11.13%318.50M
-15.56%316.58M
-6.69%332.34M
-10.03%335.55M
-3.97%358.38M
-57.38%374.92M
-56.37%356.16M
-55.62%372.97M
-56.28%373.19M
8.46%879.66M
-6.53%816.30M
12.86%840.33M
8.39%853.54M
7.71%811.07M
15.02%873.30M
Total equity
-105.72%-60.00M
-3.07%1.03B
4.47%1.08B
2.51%1.06B
4.22%1.05B
11.12%1.06B
10.93%1.03B
12.39%1.04B
10.41%1.01B
4.08%957.45M
1.87%929.17M
3.98%921.52M
6.96%912.19M
9.33%919.91M
10.10%912.15M
8.62%886.20M
5.22%852.80M
7.11%841.43M
9.81%828.45M
9.53%815.85M
Cash Flow Statement
Net operating income
255.68%96.00M
-108.22%-4.81M
117.41%66.52M
-55.27%19.86M
-215.22%-61.66M
64.31%58.53M
-20.32%30.60M
-1.23%44.41M
49.18%53.52M
288.75%35.62M
-21.83%38.40M
63.10%44.96M
159.19%35.88M
-126.54%-18.87M
1041.93%49.13M
-43.47%27.56M
436.76%13.84M
53.69%71.12M
-88.12%4.30M
52.70%48.76M
Net investment
-128.74%-14.00M
123.18%7.09M
-151.50%-19.22M
-306.00%-51.31M
163.25%48.71M
37.01%-30.61M
172.29%37.32M
80.85%-12.64M
-322.36%-77.01M
-180.59%-48.59M
-121.53%-51.62M
-35.30%-65.98M
142.12%34.63M
484.57%60.30M
442.61%239.78M
-164.05%-48.77M
-1341.65%-82.23M
80.62%-15.68M
2.04%-69.99M
54.28%76.13M
Net financing
-100.00%0.00
-870.05%-7.20M
142.60%9.12M
44.75%8.53M
585.14%21.07M
-43.61%935.00K
-1462.99%-21.40M
439.38%5.89M
1436.96%3.08M
100.35%1.66M
-98.04%1.57M
-61.40%1.09M
-103.56%-230.00K
-21169.78%-478.92M
463.86%80.17M
102.07%2.83M
387.54%6.46M
-17.32%2.27M
-1080.60%-22.03M
-4555.52%-136.74M

Revenue

By Business

Period:
No Data

By Region

Period:
No Data

FAQs

What is the total revenue of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 1.24B, with a year-on-year change of 661.82M.

What are the current assets of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its current assets were 652.00M, with a year-on-year change of -4.97.

What are the total assets of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its total assets of Supernus Pharmaceuticals Inc were 1.20B, with a year-on-year change of -12.21.

What are the total liabilities of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Supernus Pharmaceuticals Inc were 1.30B, with a year-on-year change of 290.86.

What is the total equity of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its total equity of Supernus Pharmaceuticals Inc was -98.00M, with a year-on-year change of -109.46.

What is the net operating income of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Supernus Pharmaceuticals Inc was 314.00M, with a year-on-year change of 271.79.

What is the net investment of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net investment of Supernus Pharmaceuticals Inc was -66.00M, with a year-on-year change of 65.24.

What is the net financing of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net financing of Supernus Pharmaceuticals Inc was -30.00M, with a year-on-year change of -346.04.

What is the Earnings Per Share (EPS) of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was 1.68, with a year-on-year change of 25.32.

What is the net income of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net income was 210.00M, with a year-on-year change of 184.30.

What is the net margin of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was 16.95, with a year-on-year change of 51.86.

What is the gross margin of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 84.10, with a year-on-year change of 8.11.

What is the Return on Equity (ROE) of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was -3.68, with a year-on-year change of -148.70.

What is the Return on Assets (ROA) of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was 16.69, with a year-on-year change of 198.84.

What is the operating profit of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its operating profit was 314.00M, with a year-on-year change of 271.79.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy